Explore more
News
FDA, COPD and Nucala
Digest more
While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.
The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...
The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...
At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...
GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended Blenrep ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback